Galvanize Therapeutics enrolls first patient in PROPEL Registry for Aliya pulsed electric field ablation in soft tissue lesions

Galvanize Therapeutics has announced the enrollment of the first patient in the PROPEL Registry, a multicenter observational study designed to evaluate the real-world safety, efficacy, and clinical adoption of its Aliya Pulsed Electric Field (PEF) ablation system for soft tissue lesions. The study, which is set to enroll up to 1,000 patients across as many as 50 U.S. centers, will track outcomes for a period of up to 24 months, marking a major milestone in the company’s effort to expand the clinical relevance of nonthermal ablation in oncology and interventional medicine.

The first procedure under the registry was successfully completed at Duke University Medical Center by Dr. Kamran Mahmood, Director of Interventional Pulmonology and Associate Professor of Medicine. The enrollment underscores a growing clinical shift toward applying pulsed electric field technology not only in arrhythmia treatment but also in solid tumor management, where minimizing collateral tissue damage has long been a challenge.

Why is pulsed electric field ablation emerging as a new frontier for treating lung, liver, and metastatic soft tissue lesions?

Aliya PEF ablation represents a departure from conventional thermal ablation techniques such as radiofrequency or microwave ablation, which rely on heat to destroy tumors but often damage adjacent tissue. By using short, high-voltage electrical pulses, Aliya selectively induces cell death while preserving sensitive surrounding structures including airways, vessels, and pleura. This preservation of the extracellular matrix allows for safer treatment in anatomically complex regions, including previously irradiated sites where options have historically been limited.

The system can be delivered percutaneously or endoscopically, enhancing procedural flexibility. Preclinical and early clinical evidence has also indicated that pulsed electric field ablation may stimulate immunologic activity through antigen release, potentially adding an immune-oncology dimension to its utility. This immunomodulatory effect has been closely watched by researchers seeking to combine local tumor ablation with systemic immune response activation.

From a historical perspective, pulsed electric field applications first gained traction in cardiac electrophysiology, where their ability to ablate arrhythmic tissue with lower complication rates sparked widespread industry adoption. The pivot into oncology reflects a broader movement to diversify PEF into multiple disease areas, positioning companies like Galvanize at the convergence of interventional oncology and immunotherapy.

How does the PROPEL Registry aim to advance clinical adoption and evidence-based integration of Aliya ablation?

The PROPEL Registry is designed as a pragmatic, multicenter observational study, systematically collecting data on procedural techniques, perioperative outcomes, and radiographic responses. According to Galvanize’s Chief Medical Officer Dr. Bill Krimsky, the goal is to capture not just efficacy but also the lived experience of physicians as they integrate Aliya into daily clinical pathways. By including heterogeneous patient populations, the registry offers a broader perspective than tightly controlled prospective trials, reflecting how the system will perform in diverse real-world settings.

Planned endpoints include safety outcomes, local tumor control rates, and overall survival metrics, along with secondary endpoints related to immune responses and quality of life measures. With follow-up extending to two years, the dataset could provide one of the most comprehensive evaluations of PEF in oncology to date. Analysts believe the registry could play a pivotal role in informing reimbursement discussions and in positioning Aliya as a mainstream modality within interventional oncology.

Institutional sentiment appears cautiously optimistic. While registries are observational and therefore not designed to provide the same level of causal inference as randomized controlled trials, they are increasingly valued by payers, regulators, and clinicians for capturing data at scale. If PROPEL demonstrates consistent safety and efficacy across diverse tumor sites, it could accelerate guideline inclusion and expand addressable markets for Galvanize.

What does Aliya’s positioning reveal about Galvanize Therapeutics’ broader growth strategy in interventional medicine?

Galvanize Therapeutics, headquartered in Redwood City, California, has articulated its mission to become a global leader in biologically driven energy-based therapies. The company’s pipeline spans chronic bronchitis symptom relief, cardiac arrhythmia treatment, and solid tumor ablation, reflecting a portfolio strategy that balances pulmonary disease, cardiovascular care, and oncology. This diversified focus positions the firm across several high-burden therapeutic categories, each with growing demand for minimally invasive technologies.

By leveraging the Aliya system’s nonthermal approach, Galvanize is directly addressing limitations in current tumor ablation paradigms. Market research indicates that thermal ablation faces procedural constraints in up to 30% of cases due to proximity to critical structures. With Aliya’s ability to spare non-target tissue, institutional investors see potential for increased adoption in cases previously deemed unsuitable for ablation.

From a financial lens, PEF oncology represents an underpenetrated growth frontier. According to industry estimates, the global tumor ablation market was valued at approximately USD 1.5 billion in 2024 and is projected to grow at a compound annual growth rate of over 10%. If Aliya achieves broad uptake, Galvanize could capture a meaningful share of this expanding market. Analysts have noted that reimbursement alignment will be key, making real-world data from PROPEL central to the company’s strategy.

How are institutional investors and market sentiment responding to Galvanize’s move into large-scale registries?

Although Galvanize Therapeutics remains privately held, institutional interest in the pulsed electric field segment has grown sharply. Investors recognize that PEF technology has already proven disruptive in cardiology through widespread adoption in atrial fibrillation ablation. The extension of the technology to oncology is seen as a logical expansion that could drive significant value creation.

Early reactions among medical technology investors suggest confidence in Galvanize’s ability to scale Aliya through registry-backed evidence generation. The decision to launch a registry of up to 1,000 patients signals confidence in both the technology’s safety profile and the clinical appetite for adoption. Some institutional observers have suggested that strong registry results could position Galvanize as an attractive acquisition target for larger medical device conglomerates seeking to broaden their oncology portfolios.

In terms of broader market sentiment, PEF oncology is often compared to the trajectory of stereotactic body radiation therapy (SBRT), which also transitioned from niche use to widespread adoption once large datasets validated its safety and efficacy. Analysts expect a similar adoption curve for PEF if Galvanize demonstrates durable outcomes in PROPEL and subsequent studies.

What are the long-term implications for patients and the oncology treatment landscape if pulsed electric field ablation gains traction?

For patients, the primary benefit of Aliya PEF lies in access to minimally invasive ablation options that avoid the collateral tissue damage associated with heat-based approaches. This could be particularly meaningful for patients with lesions in anatomically sensitive regions or those who have already undergone radiation therapy, where treatment options are limited.

If the immunomodulatory potential of PEF is further validated, Aliya could also serve as a bridge technology that enhances the efficacy of systemic immunotherapies. Oncologists are increasingly interested in strategies that combine local tumor control with systemic immune activation, and Aliya could become part of combination regimens that extend beyond focal ablation.

In the long run, registry-backed validation could pave the way for expanded indications beyond lung and liver tumors, including metastatic lesions in other organs. This expansion aligns with the broader oncology trend of moving toward organ-agnostic therapies that prioritize mechanism of action over tumor site.